Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity

scientific article published on 03 September 2011

Hydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1136/EBM.2011.100104
P698PubMed publication ID21891796

P2093author name stringDeepa Manwani
P433issue2
P921main subjecthydroxycarbamideQ212272
DactylitisQ517782
P304page(s)37-38
P577publication date2011-09-03
P1433published inEvidence-Based MedicineQ26841868
P1476titleHydroxycarbamide for very young children with sickle cell anaemia: no effect on the primary outcomes of spleen or kidney function, but evidence for decreased pain and dactylitis, with minimal toxicity
P478volume17

Reverse relations

cites work (P2860)
Q24604028Evidence review of hydroxyurea for the prevention of sickle cell complications in low-income countries
Q38696578Interventions for chronic kidney disease in people with sickle cell disease.

Search more.